Andy Plump, Takeda president of R&D (Jeff Rumans)

Take­da spins out a pipeline of ‘in­ter­est­ing but still dif­fi­cult’ psych drugs in $2B deal as it wraps up a post-merg­er R&D shake­out

Back at JP Mor­gan in Jan­u­ary, I had a sit-down with Take­da R&D chief Andy Plump, who spelled out plans to li­cense out rights to a slate of ex­per­i­men­tal psy­chi­a­try drugs — one of the last R&D deals left to be done af­ter the big Shire buy­out was com­plet­ed a year be­fore.

The ther­a­pies, he told me, were “very in­ter­est­ing but still dif­fi­cult.” And now they are in the hands of Neu­ro­crine Bio­sciences, which will ex­plore their full po­ten­tial af­ter com­mit­ting to a $2 bil­lion deal to see ex­act­ly what they are worth.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.